Shaker Investments LLC OH Has $4.50 Million Stake in iRadimed Corporation $IRMD

Shaker Investments LLC OH boosted its holdings in iRadimed Corporation (NASDAQ:IRMD) by 18.9% in the third quarter, Holdings Channel reports. The firm owned 63,199 shares of the medical equipment provider’s stock after purchasing an additional 10,056 shares during the quarter. iRadimed comprises about 1.8% of Shaker Investments LLC OH’s holdings, making the stock its 15th biggest position. Shaker Investments LLC OH’s holdings in iRadimed were worth $4,497,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. CWM LLC boosted its stake in shares of iRadimed by 62.2% during the 3rd quarter. CWM LLC now owns 550 shares of the medical equipment provider’s stock worth $39,000 after buying an additional 211 shares during the last quarter. Albert D Mason Inc. boosted its position in iRadimed by 5.6% during the third quarter. Albert D Mason Inc. now owns 17,021 shares of the medical equipment provider’s stock valued at $1,211,000 after purchasing an additional 898 shares during the last quarter. Osaic Holdings Inc. grew its stake in iRadimed by 766.6% in the second quarter. Osaic Holdings Inc. now owns 3,813 shares of the medical equipment provider’s stock valued at $228,000 after purchasing an additional 3,373 shares in the last quarter. Ranger Investment Management L.P. increased its position in shares of iRadimed by 7.4% during the 2nd quarter. Ranger Investment Management L.P. now owns 214,840 shares of the medical equipment provider’s stock worth $12,845,000 after purchasing an additional 14,730 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its position in shares of iRadimed by 191.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock worth $45,000 after purchasing an additional 495 shares during the last quarter. 92.34% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, CEO Roger E. Susi sold 5,000 shares of iRadimed stock in a transaction that occurred on Monday, December 22nd. The stock was sold at an average price of $96.73, for a total transaction of $483,650.00. Following the completion of the sale, the chief executive officer directly owned 2,287,500 shares of the company’s stock, valued at approximately $221,269,875. This trade represents a 0.22% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO John Glenn sold 15,000 shares of the company’s stock in a transaction on Thursday, December 11th. The shares were sold at an average price of $97.29, for a total value of $1,459,350.00. Following the completion of the transaction, the chief financial officer directly owned 7,362 shares in the company, valued at approximately $716,248.98. This represents a 67.08% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 65,000 shares of company stock worth $5,548,150. 36.80% of the stock is owned by corporate insiders.

iRadimed Price Performance

NASDAQ:IRMD opened at $97.45 on Friday. The company has a market cap of $1.24 billion, a P/E ratio of 59.06 and a beta of 1.06. The firm’s fifty day moving average price is $88.72 and its two-hundred day moving average price is $74.24. iRadimed Corporation has a one year low of $47.48 and a one year high of $98.44.

iRadimed (NASDAQ:IRMD) last announced its earnings results on Monday, November 3rd. The medical equipment provider reported $0.47 EPS for the quarter, topping the consensus estimate of $0.43 by $0.04. iRadimed had a net margin of 26.31% and a return on equity of 22.93%. The business had revenue of $21.20 million during the quarter, compared to the consensus estimate of $20.50 million. iRadimed has set its Q4 2025 guidance at 0.470-0.510 EPS and its FY 2025 guidance at 1.840-1.880 EPS. As a group, equities research analysts expect that iRadimed Corporation will post 1.66 earnings per share for the current year.

iRadimed Dividend Announcement

The company also recently announced a special dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Wednesday, December 17th will be given a $0.50 dividend. The ex-dividend date of this dividend is Wednesday, December 17th. iRadimed’s dividend payout ratio is presently 41.21%.

Wall Street Analysts Forecast Growth

IRMD has been the subject of several recent analyst reports. Wall Street Zen downgraded iRadimed from a “strong-buy” rating to a “buy” rating in a report on Sunday, October 26th. Zacks Research upgraded shares of iRadimed to a “hold” rating in a research note on Tuesday, November 4th. Lake Street Capital restated a “buy” rating and set a $100.00 price objective on shares of iRadimed in a research note on Monday, November 3rd. Roth Capital set a $90.00 target price on shares of iRadimed in a report on Friday, October 31st. Finally, Weiss Ratings reiterated a “buy (b-)” rating on shares of iRadimed in a report on Monday, December 22nd. Four investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $87.33.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.